VELETRI Global Market Report 2026

VELETRI (epoprostenol) is a prostacyclin vasodilator prescribed for pulmonary arterial hypertension (PAH). It works by relaxing blood vessels in the lungs, reducing blood pressure, and enhancing blood flow. In contrast to Flolan, VELETRI does not need to be refrigerated, offering greater convenience for continuous infusion. It is given intravenously to help improve exercise tolerance and alleviate symptoms in patients with PAH.

The main product forms of VELETRI are injectable and inhalation. Veletri injectable is a prostacyclin (epoprostenol) therapy used to treat pulmonary arterial hypertension (PAH), helping to improve exercise capacity and alleviate symptoms. Its applications include pulmonary arterial hypertension and other related conditions, and the products are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have increased the cost of imported prostacyclin APIs and infusion related components used in injectable and inhalation therapies. These impacts are most pronounced in North America and Europe, where production depends on specialized and tightly regulated supply chains. Rising tariff related expenses have influenced manufacturing costs, pricing strategies, and procurement planning for pulmonary vascular disease treatments. This has affected availability and affordability across hospital and specialty care settings. Positively, tariffs are supporting local pharmaceutical manufacturing initiatives, expanded domestic production capacity, and stronger regional supply chain resilience over the long term.

The veletri market research report is one of a series of new reports from The Business Research Company that provides veletri market statistics, including veletri industry global market size, regional shares, competitors with a veletri market share, detailed veletri market segments, market trends and opportunities, and any further data you may need to thrive in the veletri industry. This veletri market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veletri market size has grown strongly in recent years. It will grow from $1.45 billion in 2025 to $1.56 billion in 2026 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to clinical efficacy of epoprostenol, rising diagnosis of pah, hospital reliance on iv prostacyclins, limited oral alternatives, improved pah survival rates.

The veletri market size is expected to see strong growth in the next few years. It will grow to $2.07 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to increasing pah prevalence, growth in specialty pah centers, rising demand for stable formulations, expansion of infusion therapy adoption, increased awareness of pah. Major trends in the forecast period include growing adoption of non-refrigerated prostacyclin therapies, increased use of continuous infusion pah treatments, rising demand for advanced pah vasodilators, expansion of hospital-based pah management, increased focus on improving pah patient mobility.

The rising prevalence of venous diseases is expected to drive the growth of the VELETRI market in the coming years. Venous diseases are disorders in which the veins experience impaired blood flow, leading to swelling, pain, and potential complications such as varicose veins and deep vein thrombosis. The increase in venous disease cases is influenced by factors including an aging population, sedentary lifestyles, obesity, and enhanced diagnostic capabilities. Veletri is utilized to improve exercise capacity and alleviate symptoms in patients with venous diseases affecting the pulmonary vasculature. For example, in January 2025, the Centers for Disease Control and Prevention, a US-based government organization, reported that up to 900,000 individuals in the United States are affected by venous thromboembolism (VTE) annually, with an estimated 60,000 to 100,000 deaths attributed to VTE each year. Consequently, the growing prevalence of venous diseases is supporting the expansion of the VELETRI market.

The increasing healthcare expenditure is expected to drive the growth of the VELETRI market in the coming years. Healthcare expenditure refers to the total financial resources allocated to medical goods and services to maintain and enhance population health. Healthcare spending is rising as an aging population requires more frequent medical attention and long-term health services. Higher healthcare expenditure enables greater use of VELETRI by improving access to specialized PAH care, expanding reimbursement for high-cost therapies, and strengthening the clinical infrastructure necessary for continuous IV treatment. For example, in April 2025, according to the Office for National Statistics, a UK government department, total healthcare spending increased by 6.5% in nominal terms and by 2.4% in real terms between 2023 and 2024 after adjusting for inflation. Thus, the rising healthcare expenditure is driving the growth of the VELETRI market.

Major companies operating in the Veletri space are concentrating on broadening access through generic formulations, such as FDA-approved epoprostenol sodium injection, to offer more affordable treatment options for patients with pulmonary arterial hypertension. Generic Veletri refers to therapeutically equivalent versions of the branded epoprostenol product that comply with FDA standards for quality, safety, and efficacy, delivering the same clinical outcomes at a reduced cost. For example, in October 2025, Mylan Pharmaceuticals, a US-based pharmaceutical firm, received FDA approval for its generic Veletri (epoprostenol sodium) injection. The product is available in multiple vial strengths, including 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL, and provides the same prostacyclin mimetic activity as the branded version, supporting improved exercise tolerance and symptom management in PAH patients.

Major companies operating in the veletri market are Johnson & Johnson, Bayer Pharma AG, Novartis AG, GlaxoSmithKline plc, Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Sandoz International GmbH, Sun United Therapeutics Corporation, Actelion Pharmaceuticals Ltd., Bayer Pharma AG, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Johnson & Johnson, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Euroapi S.A., Pfizer CentreOne, Sai Life Sciences Limited, Zhejiang Ausun Pharmaceutical Co. Ltd., Yonsung Fine Chemicals Co. Ltd., Cayman Pharma S.r.o., Nichi-Iko Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Hikma Pharmaceuticals plc

North America was the largest region in the VELETRI market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veletri market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the veletri market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The VELETRI market consists of sales of injections, biosimilars, infusion systems, and related equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

VELETRI Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses veletri market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for veletri ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The veletri market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Formulation Stability Type: Room-Temperature Stable Formulation; Refrigeration-Required Formulation
• 2) By Treatment Setting: Hospitals; Specialized Pulmonary Hypertension Centers
• 3) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
• Subsegments:
• 1) By Room-Temperature Stable Formulation: Ready-to-Use Formulation; Extended Stability Infusion Solution
• 2) By Refrigeration-Required Formulation: Reconstituted Cold-Chain Formulation; Limited-Stability Infusion Solution
• Companies Mentioned: Johnson & Johnson; Bayer Pharma AG; Novartis AG; GlaxoSmithKline plc; Gilead Sciences Inc.; Teva Pharmaceutical Industries Ltd.; Boehringer Ingelheim International GmbH; Sandoz International GmbH; Sun United Therapeutics Corporation; Actelion Pharmaceuticals Ltd.; Bayer Pharma AG; GlaxoSmithKline plc; Novartis AG; Pfizer Inc.; Johnson & Johnson; Sandoz International GmbH; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Euroapi S.A.; Pfizer CentreOne; Sai Life Sciences Limited; Zhejiang Ausun Pharmaceutical Co. Ltd.; Yonsung Fine Chemicals Co. Ltd.; Cayman Pharma S.r.o.; Nichi-Iko Pharmaceutical Co. Ltd.; Dr. Reddy's Laboratories Ltd.; Aurobindo Pharma Ltd.; Hikma Pharmaceuticals plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.